These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3309736)

  • 1. The physiopathologic significance of manganese in brain: its relation to schizophrenia and neurodegenerative disorders.
    Donaldson J
    Neurotoxicology; 1987; 8(3):451-62. PubMed ID: 3309736
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism.
    Chiueh CC; Miyake H; Peng MT
    Adv Neurol; 1993; 60():251-8. PubMed ID: 8380519
    [No Abstract]   [Full Text] [Related]  

  • 3. [New clues to the etiology of Parkinson disease: parkinsonism induced by the neurotoxin MPTP].
    Jonsson G; Sundström E
    Lakartidningen; 1986 Jan; 83(4):215-8. PubMed ID: 3485230
    [No Abstract]   [Full Text] [Related]  

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for research on schizophrenia. V. Pharmacological observations, Drug-induced psychoses.
    Snyder SH; Aghajanian GK; Matthysse S
    Neurosci Res Program Bull; 1972 Nov; 10(4):430-45. PubMed ID: 4663824
    [No Abstract]   [Full Text] [Related]  

  • 6. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of NMDA receptors and the phencyclidine model of schizophrenia.
    Thornberg SA; Saklad SR
    Pharmacotherapy; 1996; 16(1):82-93. PubMed ID: 8700797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa, manganese, and degenerations of the brain.
    Cotzias GC
    Harvey Lect; 1974; 68():115-47. PubMed ID: 4452625
    [No Abstract]   [Full Text] [Related]  

  • 9. Biochemical mechanisms underlying MPTP-induced and idiopathic parkinsonism. New vistas.
    Singer TP; Ramsay RR; Sonsalla PK; Nicklas WJ; Heikkila RE
    Adv Neurol; 1993; 60():300-5. PubMed ID: 8380523
    [No Abstract]   [Full Text] [Related]  

  • 10. Taurine fails to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion in mice.
    Navneet AK; Appukuttan TA; Pandey M; Mohanakumar KP
    Amino Acids; 2008 Aug; 35(2):457-61. PubMed ID: 17701098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ascorbic acid on dopamine level in the mouse brain after intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Smiałek M; Bugera-Piecuch TE; Kosicka B
    Neuropatol Pol; 1987; 25(3):299-304. PubMed ID: 3502483
    [No Abstract]   [Full Text] [Related]  

  • 12. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of heart norepinephrine in mice by some analogs of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
    Fuller RW; Hemrick-Luecke SK
    Res Commun Chem Pathol Pharmacol; 1987 May; 56(2):147-56. PubMed ID: 3496637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
    Schmidt N; Ferger B
    Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.
    Himeda T; Kadoguchi N; Kamiyama Y; Kato H; Maegawa H; Araki T
    Neuropharmacology; 2006 Mar; 50(3):329-44. PubMed ID: 16303147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson-like syndrome in nonhuman primates receiving a tetrahydropyridine derivative.
    Barsoum NJ; Gough AW; Sturgess JM; de la Iglesia FA
    Neurotoxicology; 1986; 7(1):119-26. PubMed ID: 3487056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
    Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T
    Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neurochemical and clinical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in small animals.
    Donnan GA; Kaczmarczyk SJ; Solopotias T; Rowe P; Kalnins RM; Vajda FJ; Mendelsohn FA
    Clin Exp Neurol; 1986; 22():155-64. PubMed ID: 3495376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline.
    Ogunrombi MO; Malan SF; Terre'Blanche G; Castagnoli K; Castagnoli N; Bergh JJ; Petzer JP
    Life Sci; 2007 Jul; 81(6):458-67. PubMed ID: 17655878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histamine and schizophrenia.
    Arrang JM
    Int Rev Neurobiol; 2007; 78():247-87. PubMed ID: 17349864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.